Abstract
Carcinogenesis results from the long-term accumulation of genetic and epigenetic aberrations at the molecular level, which are under constant selection pressure for growth advantage. Recognizing that cancer is the result of this long-term, multi-step process provides opportunities for molecularly targeted cancer prevention. Ideally, chemopreventive agents should be low in toxicity, morbidity, and cost. Several individual agents and agent combinations are currently under evaluation in the U.S. National Cancer Institutes (NCI) chemoprevention agent development program. Nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenase (COX) -1 and -2 are among the most promising classes of agents for targeted molecular prevention.
Keywords: mf-tricyclio, colorectal carcinogenesis, apc, nin
Current Pharmaceutical Design
Title: The Role of Cyclooxygenase Inhibitors in Cancer Prevention
Volume: 8 Issue: 12
Author(s): William F. Anderson, Asad Umar, Jaye L. Viner and Ernest T. Hawk
Affiliation:
Keywords: mf-tricyclio, colorectal carcinogenesis, apc, nin
Abstract: Carcinogenesis results from the long-term accumulation of genetic and epigenetic aberrations at the molecular level, which are under constant selection pressure for growth advantage. Recognizing that cancer is the result of this long-term, multi-step process provides opportunities for molecularly targeted cancer prevention. Ideally, chemopreventive agents should be low in toxicity, morbidity, and cost. Several individual agents and agent combinations are currently under evaluation in the U.S. National Cancer Institutes (NCI) chemoprevention agent development program. Nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenase (COX) -1 and -2 are among the most promising classes of agents for targeted molecular prevention.
Export Options
About this article
Cite this article as:
Anderson F. William, Umar Asad, Viner L. Jaye and Hawk T. Ernest, The Role of Cyclooxygenase Inhibitors in Cancer Prevention, Current Pharmaceutical Design 2002; 8 (12) . https://dx.doi.org/10.2174/1381612023394935
DOI https://dx.doi.org/10.2174/1381612023394935 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Heterogeneity in the CD4 T Cell Compartment and the Variability of Neonatal Immune Responsiveness
Current Immunology Reviews (Discontinued) The Combined Use of Mesenchymal Stromal Cells and Scaffolds for Bone Repair
Current Pharmaceutical Design Insight into the Structural Requirements of Narlaprevir-Type Inhibitors of NS3/NS4A Protease Based on HQSAR and Molecular Field Analyses
Combinatorial Chemistry & High Throughput Screening COVID-19 and Renal Diseases: An Update
Current Drug Targets L-Arginine Analogs – Inactive Markers or Active Agents in Atherogenesis?
Cardiovascular & Hematological Agents in Medicinal Chemistry Brain Molecules and Appetite: The Case of Oleoylethanolamide
Central Nervous System Agents in Medicinal Chemistry Adverse Reactions Induced by Minocycline: A Review of Literature
Current Drug Safety Long-Chain Omega-3 Fatty Acid Deficiency in Mood Disorders: Rationale for Treatment and Prevention
Current Drug Discovery Technologies Recent Advances in T Cell Adoptive Immunotherapy of Cancer
Current Cancer Therapy Reviews Biology and Impact of Signal Transducers and Activators of Transcription and Their Regulators as Targets in Cancer Therapy
Current Signal Transduction Therapy Synthesis, Antiproliferative, and Antioxidant Activities of Substituted N-[(1,3,4-Oxadiazol-2-yl) Methyl] Benzamines
Letters in Drug Design & Discovery Hemangiomas, Angiosarcomas, and Vascular Malformations Represent the Signaling Abnormalities of Pathogenic Angiogenesis
Current Molecular Medicine Pharmacogenetics and the Pharmaceutical Industry
Current Pharmaceutical Design Endostatin: Preclinical Development as an Anticancer Agent
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Biased Agonism at the Parathyroid Hormone Receptor: A Demonstration of Functional Selectivity in Bone Metabolism
Mini-Reviews in Medicinal Chemistry Novel Research Strategies of Benzimidazole Derivatives: A Review
Mini-Reviews in Medicinal Chemistry Beyond Hemostasis: The Role of Platelets in Inflammation, Malignancy and Infection
Cardiovascular & Hematological Disorders-Drug Targets Mediterranean Diet Rich in Olive Oil and Obesity, Metabolic Syndrome and Diabetes Mellitus
Current Pharmaceutical Design Sports Medicine Applications of Platelet Rich Plasma
Current Pharmaceutical Biotechnology Inhibitors for Metastasis Development
Recent Patents on Anti-Cancer Drug Discovery